Stay updated with breaking news from Marcus Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Also, the co-founder of the Black Lives Matter Global Network Foundation is stepping down as executive director, and the interim CEO of the Washington Regional Association of Grantmakers will stay on permanently.
102 Schools Selected for Phase Two of Florida Civics and Debate Initiative
(RNS) — On Monday, the first day of early registration, Justine Lieberman logged on to her computer and signed up for four days of camp. She’d been waiting for this moment for more than a year after the coronavirus scuttled her plans last summer. But unlike many other campers across the country, Lieberman is not a kid, and she is well past her teens. At 28, she’s a Los Angeles-based real estate agent, single and eager to meet new people, learn new skills and have fun. “I enjoy being around people who are my age,” said Lieberman. “For me, it’s four days of fun without the pressur...
May 20, 2021 9:54 am It was only after Abby Match was diagnosed with an aggressive form of breast cancer that she learned she was a carrier of a mutation in her BRCA1 gene associated with a significantly elevated risk for developing breast cancer at a young age. (Courtesy of Match) Advertisement After discovering a suspicious lump in her breast one day while in the shower, Abby Match was diagnosed in August with an aggressive form of breast cancer. She subsequently underwent a bilateral mastectomy, a hysterectomy, chemotherapy and radiation. It was only after she di...
E-Mail IMAGE: Fluorescence labelling of distinct layers of the brain. Each colour represents a different cell type within the cortex. view more Credit: Maria Bergamasco, WEHI. A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma. Using specifically designed receptors, researchers were able to completely clear brain cancer tumours in preclinical models, using chimeric antigen receptor (CAR) T cell therapy. Published today in Clinical & Translational Immunology and led by Associate P...